Antibiotic Identified by AI
nature.com
nature.com
- The secret sauce here was the large, high quality experimental dataset they generated.
- Chemprop is meh.
- Is a tanimoto similarity < 0.3 really dissimilar? Depends on the chemical fingerprint parameters they are using in RDkit. For ECFP4 the expected similarity of two random molecules is about 0.1. A value of 0.3 about the cutoff you would use for a similarity based virtual screening with ECFP4 fingerprints.
- The cheminformatic filtering steps that they did on their hits was well done.
- The experimental validation of the target was well done. A good illustration of all the preclinical work it takes to validate a molecule and mechanism on the way to an IND.
- They got very lucky. Most of the time your compound hits are not all that potent and require extensive med chem optimization. That was not the case here.
Do you think we will come up with AIs that can model potency? How can we further improve leveraging AI beyond discovery?
Poorly. AI does not extrapolate. It can explore defined interpolation spaces with an outcome artifact in input areas where there is little data, but typically cannot extrapolate outside of convex hulls, provided classes, or other hard boundaries very well.
In effect, you have to be crafty and clever about the space an AI is to search within.
Keep in mind that the dataset generated during optimization and the one you would prefer to train a model are quite different.
Also, in practice optimizing a lead compound is about more than just potency. You are also worried about things like toxicity, bioavailability, off target effects (selectivity), synthesis routes / yields (manufacturability), etc. And functional readouts (the assays you run) are not consistent across diseases / indications / targets / compounds.
That being said I am almost certain someone has used Bayesian optimization for an assist.
While I generally agree the data quality is poor, let's be clear: by exploting the data in PDB and Uniprot, Deepmind "solved protein structure prediction". There is a lot more value in the data that's out there, just mostly underutilized.
I really don't see what's new here (except that they found a promising compound).
The part of the abstract that I have access to doesn't say how far abaucin got in the compound screening pipeline. Has it been shown effective in vitro or in vivo? What side effects have been screened for? Does it reach the infection site? Does it survive the digestive tract? Does it interact with common foods?
Here's a wikipedia article about how high throughput drug screening works. The inputs to these processes are traditionally computationally generated:
https://en.wikipedia.org/wiki/High-throughput_screening
Choice quote from wikipedia:
The term uHTS or ultra-high-throughput screening refers (circa 2008) to screening in excess of 100,000 compounds per day.
edit: Also, what percentage of compounds generated with this computational technique make it to each stage of the screening pipeline, and how does that compare to existing computational techniques?
https://www.ctvnews.ca/health/first-canadian-trial-successfu...
Very few discuss how many lives may be lost if we regulate and slow down the progress of AI.
Rather than constantly focusing on x-risk, we should be just as often discussing the reasons to believe that life-saving and perhaps even civilization-saving breakthroughs may come about due to advances in AI technology.
https://www.cidrap.umn.edu/antimicrobial-stewardship/artific...
This link is a better and not-paywalled version from then:
I tried archive.is with no luck.
How can we have any meaningful discussion on the article without reading it?
Too bad.
https://annas-archive.org/search?q=10.1038%2Fs41589-023-0144...
As such, once the antibiotics are stopped, non-resistant bacteria may be better able to compete for resources and multiply.
There's a reason super resistant strains are most commonly found in hospital and health care settings: https://www.cdc.gov/drugresistance/biggest-threats.html
If the ongoing cost of the mutation was truly free, one would expect it to spread out beyond these places more prominently.
Edit: I may have under-emphasized that there is no guarantee, and we shouldn't rely on this property.
Why would such solutions be immune to the bacteria evolving escape?
Or does the 'final' bit means you accidentally kill us all by genetic engineering or nano bots?
The problem with bacteria is they are a moving target - it's not as if they aren't constantly under attack from all sides already.
Bacteriophage ( viruses that target bacteria ) are ubiquitous, there is bacteria on bacteria action ( in fact most current antibiotics are molecules one bacteria or fungi developed to kill another ), and organisms like us - are constantly trying to kill bacteria through multiple mechanisms.
Sure we do. We could stop giving out antibiotics like candy for every sprained ankle and cough to not cultivate resistance.
* Fitness is not a 1-D line. Every time a bacteria evolves resistance, it pays a cost for doing so (in lab experiments it's pretty easy to generate resistance by adding antibiotics, and the resistance factors disappear very quickly once the antibiotic is removed, suggesting a fitness cost). So even while they're getting harder to treat they're also getting less robust in general.
I never thought about it this way but this is really insightful. I was assuming it will be an endless war but if the cost gets prohibitively high to maintain resistance we have a real advantage